Regeneron Pharmaceuticals (NQ:REGN)

Regeneron Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Regeneron Pharmaceuticals Stock Sees A Relative Strength Rating Rise ↗

December 06, 2023

The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.

You Don't Have to Pick a Winner in Gene-Editing. Do This Instead. ↗

December 04, 2023

Via The Motley Fool

GOOG Stock Alert: Alphabet Is Spending Money in All the Wrong Places ↗

December 02, 2023

The company continues to buy back Alphabet stock in large quantities. As for its other equity investments, it ought to stick with the S&P 500.

Via InvestorPlace

Topics Stocks

11 Analysts Have This to Say About Regeneron Pharmaceuticals ↗

November 28, 2023

Via Benzinga

If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today ↗

November 17, 2023

Via Benzinga

How Is The Market Feeling About Regeneron Pharmaceuticals? ↗

November 16, 2023

Via Benzinga

Where Regeneron Pharmaceuticals Stands With Analysts ↗

November 09, 2023

Via Benzinga

$1000 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today ↗

December 01, 2023

Via Benzinga

Regeneron to Host Investor Call and Webcast on December 14, 2023 to Provide Updates Across Its Hematology Portfolio

November 30, 2023

We are having a great but choppy market recovery over the past four weeks and it looks like it should continue through to the next earnings cycle in January.

Biotech And Healthcare Portfolio Playbook For December 2023/24 ↗

November 27, 2023

Via Talk Markets

Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales ↗

November 27, 2023

Regeneron and Sanofi are partnered on Dupixent, a treatment for conditions tied to type 2 inflammation.

Sanofi/Regeneron's Blockbuster Prescription Drug Dupixent Shows Additional Promise In Chronic Lung Disorder ↗

November 27, 2023

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) announced the second Dupixent (dupilumab) Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) showed that...

Via Benzinga

2 Soaring Stocks to Buy and Hold ↗

November 09, 2023

Both of these companies crushed earnings season.

Via The Motley Fool

Regeneron Edges Higher On Third-Quarter Beat As High-Dose Eylea Delivers ↗

November 02, 2023

The launch of high-dose Eylea is off to a strong start in the U.S.

Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease

November 27, 2023

9 Health Care Stocks With Whale Alerts In Today's Session ↗

November 16, 2023

Via Benzinga

Regeneron Announces Investor Conference Presentation

November 15, 2023

Regeneron Commits $34 Million Over Five Years to Continue to Sponsor the Regeneron International Science and Engineering Fair (ISEF)

November 13, 2023

With questions rising about the economy, investors may consider undervalued biotech stocks for their relative insulation factor.

7 Underappreciated Biotech Stocks to Pick Up on the Cheap ↗

November 09, 2023

Via InvestorPlace

Topics Economy

3 Biotech Stocks That Are Betting on the Future of Gene Editing ↗

November 09, 2023

These three companies have gene editing therapies in late-stage clinical trials, making them promising biotech stocks to buy right now.

Via InvestorPlace

Celldex Makes A Bullish Move As It Looks To Take On Regeneron, Sanofi ↗

November 06, 2023

The company is looking to take on Regeneron and Sanofi's Dupixent in skin diseases.

Adverum Biotechnologies Inc (NASDAQ: ADVM) revealed updated data from the OPTIC extension study of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) in patients with wet AMD during...

Why Is Eye Disease-Focused Adverum Bio Stock Trading Higher Today? ↗

November 06, 2023

Via Benzinga

Regeneron Pharmaceuticals Stock Upgraded After Q3, But There Is A Headwind - Analyst Review ↗

November 03, 2023

Thursday, Regeneron Pharmaceuticals Inc (NASDAQ: REGN) reported better-than-

Via Benzinga

Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review ↗

November 03, 2023

Bulls are back in control as the major indexes confirmed the uptrend this week.

Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH

November 03, 2023

Regeneron's Skin Drugs Propel Revenue In Q3, Witnesses Strong Demand For Higher Dose Version Of Flagship Eye Drug ↗

November 02, 2023

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned Q3 adjusted EPS of $11.59, up 4% Y/Y, beating the $10.77 Street estimate

Via Benzinga

US Stocks On Track For Solid Start Amid Lingering Fed Optimism: Traders Eye Earnings From Market Bellwether Apple ↗

November 02, 2023

After the Federal Reserve‘s decision, the stock market rally is poised to gain momentum on Thursday, with stock futures indicating an uptick.

Via Benzinga

Topics Economy

1 Supercharged Growth Stock That Could Make You a Millionaire in 10 Years ↗

November 02, 2023

Biotech may be in a slump, but this innovator holds enormous promise as a potential wealth escalator.

Via The Motley Fool

Regeneron Reports Third Quarter 2023 Financial and Operating Results

November 02, 2023